Brain injury. Intracranial injury
Conditions
Interventions
Intervention 1: Intervention group: Patients in drug group will be received Melatonin tablet (Razak Pharmaceutical company, Tehran, Iran), 20 mg daily for 5 days. Intervention 2: Control group: Patien
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients (age more than 18) who had traumatic brain injury included skull fracture, subdural hemorrhage, subarachnoid hemorrhage, brain contusion and laceration, intracerebral hemorrhage, intraventricular hemorrhage and traumatic axonal injury Non-traumatic brain injury included strokes, infections, hypoxia and brain tumors Admission within 72 hours after brain injury in intensive care unit or other wards such as neurology or neurosurgery Healthy gastrointestinal tract (capable of oral ingestion or gavage of drug)
Exclusion criteria
Exclusion criteria: Length of hospitalization less than 5 days in intensive care units or other wards Hypersensitivity to melatonin Hepatic failure (class C according to Child-pugh) Renal failure (need dialysis) Severe heart failure (Class 3 and 4 according to Newyork heart association) Sepsis within first 5 days of admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in bio markers of mitochondrial injury. Timepoint: Day 1 and 5 of intervention. Method of measurement: Elisa kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality rate of patients. Timepoint: 28 days. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSarah Mousavi
Esfahan University of Medical Sciences
Outcome results
None listed